NASDAQ
27.96USD
+0.29 (+1.05%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.3B
P/E
—
EPS
—
Beta
0.11
52W range
23.05-42.205
Day range
27.51–28.23
Open
28.05
Prev close
27.67
Volume
555K
Avg volume
1.3M
Dividend
0.00
IPO
2021-02-09
https://seekingalpha.com/article/4931177-newamsterdam-pharma-company-n-v-nams-analyst-investor-day-transcript · 8/9/2026+0.00
https://www.prnewswire.com/news-releases/newamsterdam-pharma-und-die-menarini-group-erhalten-positive-stellungnahme-des-chmp-mit-der-empfehlung-zur-erteilung-einer-zulassung-fur-ubeslo-obicetrapib-monotherapie-und-evlarco-festsatzkombination-aus-obicetrapib-und-ezet-302834758.html · 7/26/2026+1.00
https://seekingalpha.com/article/4925643-newamsterdam-pharma-obicetrapib-is-more-than-another-ldl-lowering-pill · 7/26/2026+0.40
https://seekingalpha.com/article/4913476-newamsterdam-pharma-company-n-v-nams-presents-at-goldman-sachs-47th-annual-global-healthcare · 6/10/2026+0.10
https://seekingalpha.com/article/4902015-newamsterdam-pharma-company-n-v-nams-discusses-clinical-development-update-and-interim · 5/10/2026+0.00
https://www.globenewswire.com/news-release/2025/12/05/3200971/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html · 12/5/2025+0.10
https://seekingalpha.com/article/4819178-newamsterdam-pharma-company-n-v-nams-presents-at-citis-biopharma-back-to-school-conference · 9/4/2025+0.00
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
